Lilly's Basaglar Becomes A Blockbuster
Global Sales Of Follow-On Insulin Glargine Grow By Two-Fifths In 2019
Quarterly global Basaglar sales rose above $300m for the first time in the fourth quarter of 2019, with full-year turnover pushing the insulin glargine hybrid well into blockbuster territory.
You may also be interested in...
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
While the latest IQVIA data points to accelerated uptake of US biosimilars over the next five years, with associated increases in spending and savings, local off-patent industry association the AAM says the report raises a “red flag” over long-term market sustainability.
Mylan and Biocon have launched their Semglee version of insulin glargine in the US, revealing pricing details for the Lantus rival. At the same time, the firms have offered an update on their attempts to have Semglee classified as a biosimilar as they seek an interchangeability designation.